Institutional-grade business quality — a perfect 9-out-of-9 Piotroski health score, free cash flow well above net income, and four consecutive earnings beats averaging 28% above consensus — supports a fundamentally sound franchise in a bullish technical breakout; with only 2% headroom to the analyst consensus target, however, the geometry limits the setup to existing holders awaiting a re-rating catalyst.
Thesis pillars
- Sustained Earnings Beat Cadence→Stable
- Institutional Quality Fundamentals→Stable
- Thin Upside Limits Entry→Stable
- +1 more pillar — see the Why tab for full reasoning
Biogen Inc. (BIIB) Stock Analysis
Breakout setup · Catalyst-Driven edge
Healthcare · Drug Manufacturers - General
Hold if already holding. Not a fresh buy at $207.68, but acceptable to hold if already in. Reason: Analyst target reached - limited upside remaining.
Biogen develops and markets drugs for MS (TYSABRI, VUMERITY, AVONEX, PLEGRIDY, TECFIDERA), rare diseases (SPINRAZA for SMA, SKYCLARYS for FA, QALSODY for ALS), and co-commercializes LEQEMBI for Alzheimer's with Eisai. Revenue comes from product sales plus financial rights to... Read more
Hold if already holding. Not a fresh buy at $207.68, but acceptable to hold if already in. Reason: Analyst target reached - limited upside remaining. Chart setup: Golden cross, above all MAs, RSI 58, MACD bullish. Maintain position. Not compelling to add more. Score 5.7/10, moderate confidence.
Passes 5/7 gates (positive momentum, clean insider activity, earnings proximity 23d clear, semi cycle peak clear, materials cycle peak clear). Fails on favorable risk/reward ratio. Suitability: moderate.
About Biogen Inc.
About Biogen Inc.
Biogen markets approved drugs including TYSABRI and SPINRAZA, each accounting for more than 10% of total revenue in fiscal year 2025, across multiple sclerosis, rare neurological diseases, and Alzheimer's disease in the U.S. and international markets. LEQEMBI, co-commercialized with Eisai, received European Commission approval in April 2025 and MHRA approval in the UK in November 2025. Alcyone Therapeutics was acquired in November 2025 for approximately $85 million to advance intrathecal delivery platforms for SPINRAZA.
Biogen generates revenue through direct product sales of prescription medicines in MS and rare-disease portfolios, financial rights to Genentech/Roche anti-CD20 therapies including RITUXAN and OCREVUS, and a 50% share of LEQEMBI net sales under the Eisai collaboration. Distribution relies on specialty pharmacy channels and hospital networks, with reimbursement subject to commercial insurers, Medicare, and Medicaid. The pipeline includes felzartamab, with Phase 3 studies in IgA nephropathy (PREVAIL) and primary membranous nephropathy (PROMINENT) both initiating patient dosing in June 2025, and zorevunersen, whose Phase 3 EMPEROR study in Dravet syndrome dosed its first patient in August 2025 under the Stoke Therapeutics collaboration funded by a $165 million upfront payment.
Show full overview
Biogen faces pricing pressure from two concurrent policy mechanisms: the Inflation Reduction Act's Medicare drug-price negotiation authority and the current administration's most-favored-nation executive order, which could tie U.S. drug prices to those in lower-cost countries. The OBBBA, signed into law in July 2025, introduces additional Medicaid eligibility constraints effective in 2027 and 2028, and the company has stated it cannot determine the overall impact on operations. For MS therapies with substantial Medicare reliance, these mechanisms may weigh on net realized pricing over the medium term.
See also: Healthcare · Drug Manufacturers - General
From Biogen Inc.'s most recent 10-K filing, extracted June 9, 2026.
Recent developments
updated 2026-07-07Recent Developments — Biogen Inc.
Latest news
- NEWS Biogen Inc. (BIIB.US) 1Q Earnings and Revenue Beat Forecasts - AASTOCKS.com — AASTOCKS.com positive
- NEWS Is It Time To Reassess Biogen (BIIB) After Its Strong One Year Share Price Rally - Yahoo Finance — Yahoo Finance positive
- NEWS Biogen Had A Nearly Perfect Sales Sweep, But One Beat Really Stood Out - Investor's Business Daily — Investor's Business Daily positive
- NEWS Biogen (BIIB) Lowers 2026 Earnings Guidance Despite Q1 Sales Gro - GuruFocus — GuruFocus negative
- NEWS Biogen (BIIB) Reports Strong Q1 Earnings, Raises 2026 EPS Guidan - GuruFocus — GuruFocus positive
Generated 2026-07-07T12:21:42Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- LOWProductTYSABRI10-K Item 1: 'Product sales for TYSABRI and SPINRAZA each accounted for more than 10.0% of our total revenue for the years ended December 31, 2025'
- LOWProductSPINRAZA10-K Item 1: 'Product sales for TYSABRI and SPINRAZA each accounted for more than 10.0% of our total revenue for the years ended December 31, 2025'
Material Events(8-K, last 90d)
- 2026-03-11Item 5.02MEDIUMChief Legal Officer Susan H. Alexander to depart effective end of May 2026. Company initiated search for next Chief Legal Officer. No reason cited.SEC filing →
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
1 floor-breaker
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Hold if already holding. Not a fresh buy at $207.68, but acceptable to hold if already in. Reason: Analyst target reached - limited upside remaining. Chart setup: Golden cross, above all MAs, RSI 58, MACD bullish. Maintain position. Not compelling to add more. Target $215.33 (+3.7%), stop $194.32 (−6.9%), A.R:R -0.4:1. Score 5.7/10, moderate confidence.
Take-profit target: $215.33 (+3.3% upside). Target $215.33 (+3.7%), stop $194.32 (−6.9%), A.R:R -0.4:1. Stop-loss: $194.32.
Analyst target reached - limited upside remaining.
Biogen Inc. trades at a P/E of 23.3 (forward 13.0). TrendMatrix value score: 5.7/10. Verdict: Hold.
44 analysts cover BIIB with a consensus score of 3.8/5. Average price target: $220.
What does Biogen Inc. do?Biogen develops and markets drugs for MS (TYSABRI, VUMERITY, AVONEX, PLEGRIDY, TECFIDERA), rare diseases (SPINRAZA for...
Biogen develops and markets drugs for MS (TYSABRI, VUMERITY, AVONEX, PLEGRIDY, TECFIDERA), rare diseases (SPINRAZA for SMA, SKYCLARYS for FA, QALSODY for ALS), and co-commercializes LEQEMBI for Alzheimer's with Eisai. Revenue comes from product sales plus financial rights to anti-CD20 therapies via a Genentech collaboration.